- Home
- NVT vs GH Comparison
NVT vs GH Comparison
Compare NVT & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVT | GH |
|---|---|---|
| Founded | 1903 | 2011 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.6B | 22.9B |
| IPO Year | 2017 | 2018 |
Fundamental Metrics
Financial Performance| Metric | NVT | GH |
|---|---|---|
| Price | $168.33 | $187.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 26 |
| Target Price | ★ $204.44 | $197.04 |
| AVG Volume (30 Days) | ★ 1.7M | 1.6M |
| Earning Date | 10-30-2026 | 10-28-2026 |
| Dividend Yield | ★ 0.50% | N/A |
| EPS Growth | ★ 118.78 | 6.74 |
| EPS | ★ 2.18 | N/A |
| Revenue | ★ $3,893,100,000.00 | $982,021,000.00 |
| Revenue This Year | $40.28 | $38.21 |
| Revenue Next Year | $17.86 | $35.32 |
| P/E Ratio | $76.05 | ★ N/A |
| Revenue Growth | 29.51 | ★ 32.88 |
| 52 Week Low | $93.22 | $61.00 |
| 52 Week High | $184.64 | $183.51 |
Technical Indicators
Market Signals| Indicator | NVT | GH |
|---|---|---|
| Relative Strength Index (RSI) | 61.27 | 65.98 |
| Support Level | $145.00 | $153.88 |
| Resistance Level | $176.79 | N/A |
| Average True Range (ATR) | 5.10 | 7.38 |
| MACD | 1.19 | 0.41 |
| Stochastic Oscillator | 91.15 | 97.74 |
Price Performance
Historical ComparisonAbout NVT nVent Electric plc
NVent is a leading global provider of electrical connection and protection solutions that touch a broad range of end markets, including infrastructure, industrial, commercial, and residential. NVent designs, manufactures, markets, installs, and services a portfolio of electrical enclosures and electrical fastening solutions. North America accounts for the majority of sales.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.